Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
IMFINZI 50 mg/mL concentrate for solution for infusion
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Overall survival
Endpoint detail
Local, intrathoracic control rate, Time to discontinuation of durvalumab therapy, Toxicity, Response rates, Progression free survival, Health related quality of life (HRQoL)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.